Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesRadiology/Diagnostic ImagingBlue Cross Blue Shield TX Prior Auth Updates | Ope…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    ModifiedBlue Cross Blue Shield - TexasPolicy N/A

    Prior Authorization and Medical Necessity Updates for Advanced Imaging, Molecular Genetic, and Related Services

    Customize your policy alerts

    Sign up for all Blue Cross Blue Shield - Texas policy alerts

    Know when Blue Cross Blue Shield - Texas releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Lists CPT/HCPCS/temporary codes for advanced imaging, molecular genetic, and selected procedure categories that may require prior authorization, describes managed-by assignments (Carelon, Alacura), and notes addition of site-of-care to medical necessity criteria effective 01/01/2025.

    Policy Summary
    PayerBlue Cross Blue Shield - Texas
    PolicyPrior Authorization and Medical Necessity Updates for Advanced Imaging, Molecular Genetic, and Related Services
    Policy CodePolicy N/A
    Change TypeAdded site-of-care to medical necessitymultiple molecular/U-code assignments and vendor changes
    Effective Date01/01/2025
    Next Review DateN/A
    Key ActionSubmit prior authorization requests for listed codes to the designated manager (Carelon or Alacura) and include site-of-care information per updated medical necessity requirements.
    SourceLink
    POLICY UPDATE CHANGES

    Addition of site of care to the medical necessity criteria for numerous advanced imaging CPT codes effective 01/01/2025.

    Update Category name from "Non-Emergent Air Ambulance" to "Medical Transportation" effective 01/01/2025 and changed services management from BCBSTX to Alacura for affected codes.

    Multiple molecular genetic and U‑codes (e.g., 0575U, 0576U, 0578U, 0582U, 0583U, 0585U, 0586U, 0592U, 0597U) are assigned to "Medical Transportation" category and services management changed to Carelon/Alacura with effective add-dates (01/01/2025 and 01/01/2026 or 04/01/2025 for specific codes).

    Multiple new molecular genetic laboratory test codes (04xxxU–05xxxU and specific S/G/G codes) were added with Carelon listed as the prior authorization administrator and various effective dates (many 07/01/2025, 10/01/2025, or 04/01/2025).

    Several oncology and obstetrics noninvasive prenatal test codes (e.g., 0485U, 0486U, 0487U, 0489U, 0493U–0499U) added and marked Carelon.

    High-complexity tumor sequencing and transplant donor-derived cfDNA quantification codes (e.g., 0473U, 0538U, 0543U–0544U, 0508U–0509U) added requiring prior authorization.

    01/01/2025site-of-care effective
    Carelonprimary auth vendor
    ~120+codes listed (excerpt)
    01/01/2025category name change date
    04/01/2025scheduled retirements

    Coverage and Medical Necessity Criteria

    Prior authorization and medical necessity updates

    Listed procedures may require prior authorization and have updated medical necessity criteria

    Prior authorization list membership: Procedure code is on the payer's prior authorization list

    Presence on list does not guarantee coverage; member benefits determine final coverage

    Managed-by assignment: Many codes are managed by Carelon (or other vendors as specified) for prior authorization review

    See individual code entries for managed-by vendor

    Site-of-care update: Effective 01/01/2025, 'site of care' was added to medical necessity criteria for many imaging codes

    Applies to codes indicated in the list

    General prior authorization and medical necessity requirement (excerpt)

    Covered when prior authorization is obtained and medical necessity criteria (including site-of-care) are met

    Authorization and medical necessity: Prior authorization must be obtained through Carelon for listed CPT codes and medical necessity will be evaluated including site-of-care information effective 01/01/2025.

    Prior authorization required

    Covered when prior authorization is obtained for the listed CPT codes from the designated reviewer

    Authorization requirement: Prior authorization must be obtained from Carelon for any of the listed CPT codes before service

    Applies to the CPT codes enumerated in this section; submit to Carelon.

    Prior authorization requirement

    Listed procedures require prior authorization

    Prior authorization required: Prior authorization must be obtained for the specific CPT/HCPCS/L-codes and Category III codes listed in this section before performing or billing the service

    Many entries indicate the authorization processor (Carelon or BCBSTX).

    Prior authorization requirement

    Covered when prior authorization is obtained for listed procedures/codes and routed to the assigned services manager where indicated.

    Prior authorization requirement: Prior authorization must be obtained for the specific codes listed in this section; some codes have assigned vendor (Alacura or Carelon) and effective dates that govern authorization routing.

    No additional clinical criteria provided in this excerpt; provider must follow payer/vendor submission instructions.

    Prior authorization required

    Prior authorization required

    Prior authorization requirement: Prior authorization is required for the listed CPT codes (81345–81364, 81400–81406) and associated molecular genetic/molecular pathology tests

    Carelon is listed as the authorization vendor in multiple entries

    Panel-specific coverage criteria

    Coverage applies when panel-specific gene content and indication requirements are met

    Panel composition and indication: The genomic sequence or duplication/deletion panel must include sequencing (and where required, duplication/deletion or RNA analysis) of the minimum set of genes specified for that indication (examples: aortic dysfunction panel must include at least 9 genes; hearing loss panels must include at least 60 genes; mitochondrial gene panels must include at least 100 genes).see code-specific requirements

    Each CPT code in the list includes its own required gene list or minimum gene count.

    Coverage contingent on prior authorization

    Covered when prior authorization is obtained for the listed tests

    Authorization requirement: Tests listed in this section require prior authorization through the designated manager (Carelon) as identified next to each code

    Includes a variety of molecular/genetic CPT and proprietary codes

    Prior Authorization

    Listed molecular genetic lab testing services require prior authorization

    Prior Authorization Requirement: Prior authorization must be obtained through Carelon for the listed molecular genetic (temporary/PLA) procedure codes before claim submission.

    Each code entry includes 'Carelon' indicating the prior authorization vendor.

    Authorization requirement

    Covered when prior authorized through Carelon per payer policy

    Prior authorization requirement: Order must be prior authorized through Carelon for codes listed in this section.

    No additional clinical necessity criteria provided in these chunks.

    Prior authorization requirement for listed molecular/genetic tests

    Covered when prior authorization is obtained for the listed codes and indications as specified

    PA required: Prior authorization through Carelon is required for the listed molecular genetic testing codes before coverage will be considered.

    Effective dates provided for many codes; include code-specific effective date when requesting PA.

    Authorization requirement

    Covered when prior authorization is obtained

    Prior Authorization: Procedure code is one of the listed musculoskeletal or spine CPT codes AND prior authorization is obtained through Carelon

    Prior auth routing specified to Carelon in document excerpts

    The presence of codes on this prior authorization list does not by itself guarantee coverage under a member's benefits contract. Member benefits vary; providers should consult the member's benefit booklet or contact customer service to confirm whether a specific service is covered before scheduling or performing the procedure. Codes on this list indicate that prior authorization may be required beginning 01/01/2025 unless otherwise noted, but final coverage depends on the individual member contract.

    This excerpt does not enumerate explicit clinical denial conditions, but it makes clear that failure to obtain required prior authorization or to supply requested information (including the newly required site-of-care detail effective 01/01/2025) may result in denial of coverage for services listed under the advanced imaging/radiology codes. Providers should submit prior authorization requests to the designated administrator (Carelon when indicated) and ensure that all requested documentation is included.

    No explicit exclusion conditions for the listed codes are provided in this excerpt. The document enumerates codes that require prior authorization or routing to a specific services manager but does not list service-level exclusions within these chunks; absence of an exclusion here does not imply coverage — verify member benefits and any code-specific guidance in the full policy.

    This excerpt does not state any specific additional clinical coverage conditions beyond the requirement for prior authorization. Where molecular genetic CPT codes are listed, the document identifies authorization routing (e.g., Carelon) and, for some codes, effective or retirement dates; no further explicit exclusions are described in these segments.

    There are no explicit clinical coverage criteria or exclusions given in these chunks; instead, the molecular genetic CPT codes are listed with the authorization manager (Carelon) and — for many entries — panel composition or gene-count expectations. Coverage consideration requires that prior authorization be obtained per the listing and that any code-specific panel requirements (when noted) be met.

    Certain molecular genetic codes in this excerpt are annotated with retirement actions. For example, entries for codes such as 81433 and 81436 (and others noted in the same segment) include a retirement effective date of 04/01/2025. Providers should confirm code validity and effective/retirement dates when preparing prior authorization requests and submitting claims.

    This section of the document does not list explicit exclusions; it primarily identifies molecular/genetic test codes that require prior authorization through the named administrator (typically Carelon) and, where applicable, provides effective dates or panel composition requirements. Absence of exclusions in these chunks means providers must rely on the code-specific descriptors and the member contract to determine coverage and necessity.

    Codes and Coding Details

    Molecular Genetic CPT Codes Requiring Prior Authorization (selected)CPTCovered
    81283MLH1 gene analysis, full sequence
    81284MLH1 gene analysis, known familial variant
    81285MSH2 gene analysis, full sequence
    81286MSH2 gene analysis, known familial variant
    81287MSH6 gene analysis, full sequence
    81288MSH6 gene analysis, known familial variant
    81289PMS2 gene analysis, full sequence
    81290PMS2 gene analysis, known familial variant
    81291EPCAM deletion analysis (Lynch-related)
    81292BRCA1 gene analysis, full sequence
    1–10 of 65
    1/7
    Molecular/PLA and Proprietary Codes Requiring Prior Authorization (selected U/PLA codes)mixedCovered
    OOO1URed blood cell antigen typing DNA (35 antigens)
    OO04MScoliosis SNP panel (53 SNPs) saliva prognostic algorithm
    OOO6MHepatic mRNA expression 161 genes, algorithmic risk classifier
    OOO7MGastrointestinal neuroendocrine tumor 51-gene PCR expression nomogram
    0011MProstate mRNA assay of 12 genes (plasma/urine)
    0012MUrothelial 5-gene mRNA panel (urine)
    0071UCYP2D6 full gene sequence
    0072UCYP2D6 targeted sequence (hybrid gene)
    0073UCYP2D6 targeted sequence (2D7-2D6 hybrid)
    0074UCYP2D6 targeted analysis for non-duplicated gene
    1–10 of 20
    1/2
    Additional Molecular and Genomic Codes (selected U-codes)mixedCovered
    0211UPan-tumor DNA/RNA NGS (FFPE) interpretive report
    0212UWhole genome and mitochondrial DNA sequence analysis (rare diseases)
    0228UPhotometric multianalyte prostate molecular profile (urine)
    0236USMN1/SMN2 full gene analysis (spinal muscular atrophy)
    0339UProstate HOXC6/DLX1 mRNA assay (urine)
    0340UPersonalized MRD ctDNA minimal residual disease assay
    0489UNoninvasive prenatal fetal antigen and single-gene tests (cfDNA)
    0508UDonor-derived cfDNA (40 SNPs) plasma and urine
    0539UCTDNA 152-gene panel, whole-blood NGS
    0569UTumor methylation ctDNA (>20,000 DMRs)
    Molecular Genetic CPT & PLA Codes — Panels and High-Level Molecular Pathology (selected 814xx/815xx)CPTCovered
    81407Molecular pathology procedure level 8 (analysis of 26-50 exons)
    81410Aortic dysfunction panel — sequencing of >=9 genes (incl FBN1,TGFBR1,TGFBR2,COL3A1,MYH11,ACTA2)
    81411Duplication/deletion analysis for aortic dysfunction panel
    81412Ashkenazi Jewish disorders panel (>=9 genes)
    81413Cardiac ion channelopathy panel (>=10 genes)
    81414Cardiac ion channelopathy duplication/deletion analysis (>=2 genes)
    81415Exome sequencing (clinical)
    81416Comparator exome sequencing (e.g., parents)
    81417Re-evaluation of previously obtained exome sequence
    81418Pharmacogenomics/drug metabolism panel (>=6 genes incl CYP2C19,CYP2D6)
    1–10 of 57
    1/6

    What Providers Must Do

    Prior Authorization

    What Providers Must Do

    This list includes CPT, HCPCS, and proprietary codes for which prior authorization may be required effective January 1, 2025 (unless an alternate effective/retirement date is shown). Presence of a code on this prior authorization list does not guarantee coverage under the member's benefits contract — verify the member's benefit booklet or contact Customer Service. Failure to obtain required prior authorization may result in claim denial.

    • Prior authorization may be required for listed codes — the codes shown throughout the document are included on the payer's prior authorization list and may require prior authorization.
    • Prior authorization required — designated reviewer: Carelon — Many advanced imaging, molecular/genetic, musculoskeletal/spine, and other procedure codes listed identify Carelon as the prior authorization reviewer/authorization manager. Providers must submit requests to Carelon for those codes.
    • Codes requiring prior authorization (partial) — This section contains partial listings (examples) of CPT/HCPCS/U-codes and proprietary codes that require prior authorization; the full searchable list should be used to confirm all affected codes.
    • Prior authorization requirement for listed test codes — Molecular genetic laboratory tests and many genomic panels listed (CPT 812xx, 813xx, 814xx; U-/004xx/00xxx series) require prior authorization; each entry includes a code and a short descriptor (specialty/indication, specimen type, and testing method) to support the request.
    • Prior authorization required for listed CPT codes — Many procedure and advanced imaging CPT codes (including but not limited to CT, MRI, PET, angiography, and specialized nuclear medicine procedures) require prior authorization.

    Prior Authorization Scope

    Note
    Note
    Note
    Note
    Note
    Note
    Note

    Contrast and Study Variant Rules

    Note
    Note
    Note
    Note

    Background and Scope

    This background material explains that the file provides administrative and utilization management context for imaging and related services, including the prior authorization process and managed-by assignments. It notes the policy update effective 01/01/2025site of care to medical necessity evaluation for many advanced imaging CPT codes and repeatedly identifies Carelon (and where applicable Alacura/BCBSTX) as the authorization manager for listed codes. The document excerpt does not include detailed clinical indications within these chunks; its primary purpose here is to list codes and the operational PA routing and requirements.

    Definitions and Acronyms

    Indicator on member ID cards for Fully Insured Members effective 01/01/2026
    ID card indicator (TDI)TDI will be indicated on Fully Insured members' ID cards effective 01/01/2026
    PurposeNotation alerts providers and members to the insurer designation on ID cards for fully insured members
    ReferenceSee payer communication and ID card guidance (updated October 2025)
    PET/CT
    PET/CT definitionPositron emission tomography with concurrently acquired CT for attenuation correction and anatomical localization as described for codes 78814–78816 and 78830–78832
    Example codesCodes referenced include 78814, 78815, 78816 (PET with CT transmission) and 78830 (SPECT with CT) in the PET/CT context

    Policy Update Changes

    2025-01-01policy_update

    Effective 01/01/2025, site-of-care was added to medical necessity criteria for numerous advanced imaging CPT codes and prior authorization routing/managed-by assignments were updated (Carelon/Alacura) including renaming the category 'Non-Emergent Air Ambulance' to 'Medical Transportation'.

    2025-04-01code_effective_date

    Several molecular genetic CPT codes (e.g., 81195 and others noted in the list) were assigned specific effective or retirement dates effective 04/01/2025 as indicated in code entries.

    2025-07-01policy_update
    Policy Summary
    PayerBlue Cross Blue Shield - Texas
    PolicyPrior Authorization and Medical Necessity Updates for Advanced Imaging, Molecular Genetic, and Related Services
    Policy CodePolicy N/A
    Change TypeAdded site-of-care to medical necessitymultiple molecular/U-code assignments and vendor changes
    Effective Date01/01/2025
    Next Review DateN/A
    Key ActionSubmit prior authorization requests for listed codes to the designated manager (Carelon or Alacura) and include site-of-care information per updated medical necessity requirements.
    SourceLink
    On This Page
    Coverage and Medical Necessity CriteriaCodes and Coding DetailsWhat Providers Must DoPrior Authorization ScopeContrast and Study Variant RulesBackground and ScopeDefinitions and AcronymsPolicy Update Changes
  1. Claims for the listed procedure codes may be denied without prior authorization — Services included in this document (Medical Surgical Procedures Requiring Prior Authorization) may be denied if prior authorization is not obtained when required.
  2. Claims for the listed molecular genetic lab testing CPT codes may be denied without prior authorization — The molecular/genetic CPT, PLA, U- and J-codes listed are subject to prior authorization review by Carelon and may be denied if authorization is not obtained.
  3. Tests listed in this section are identified as "Medical Surgical Procedures Requiring Prior Authorization" and therefore will be subject to utilization management review.
  4. Submit prior authorization requests to designated reviewer — For codes managed by Carelon, providers must submit prior authorization requests to Carelon; for codes managed by BCBSTX or Alacura the document indicates the routing vendor. Site-of-care information and supporting documentation (test description, specimen type, clinical indication, panel composition when applicable) are often required.
  5. Prior authorization routing vendor is specified for many codes (Carelon or BCBSTX or Alacura) — Providers must reference the list to determine the correct services management vendor for submission.
  6. Submission routing and vendor — Prior authorization requests for advanced imaging and molecular/genetic tests are generally routed to Carelon as the vendor; some services (e.g., certain infusion or transportation codes) may be routed to Alacura or handled by BCBSTX as indicated in the list.
  7. Authorization manager and required submission — Each code entry includes the designated authorization manager (e.g., Carelon, BCBSTX, Alacura); providers must submit to the named administrator and include the code, short test/procedure descriptor, and any required clinical documentation.
  8. Provider must submit prior authorization to the listed administrator — For each molecular/genetic or procedural test identified, the provider must submit the PA request to the named reviewer (Carelon in most molecular cases) including the code and supporting documentation.
  9. Each listed procedure is identified by its code and short descriptor — Use the code and descriptor provided in the list when preparing prior authorization requests to ensure accurate routing and review.
  10. Test code and description required — When submitting PA for molecular/genetic tests, include the test code (CPT/PLA/U/J), brief test description (genes/panel and methodology), specimen type, and indication as shown in the list.
  11. Authorization routing — Verify the services management vendor in the code listing (Carelon, BCBSTX, Alacura) before submission; routing affects where and how the PA is submitted.
  12. Some specific codes include retirement or alternate effective dates — Several U-/0078U/0380U/etc. entries include retire or add effective dates (e.g., 0078U retire effective 07/01/2025; 0380U retire effective 04/01/2025; others add effective 07/01/2025 or 01/01/2026). Check the 'Updates' column for date-specific handling.
  13. Note
    Note
    Note
    Note
    Note
    Authorization vendorCarelon is listed as the prior authorization manager for PET/CT codes in the document
    Transthoracic echocardiography
    Transthoracic echocardiography codesCPT 93303, 93304, 93306, 93307 — transthoracic echocardiography for congenital anomalies and standard 2D/Doppler studies listed as requiring prior authorization
    ScopeIncludes complete and limited/follow-up transthoracic studies and related stress/contrast variants where coded
    Authorization vendorCarelon is identified as the prior authorization reviewer for these echocardiography entries
    0648T / 0649T
    0648T / 0649T descriptionQuantitative magnetic resonance for analysis of tissue composition (e.g., fat/iron/water content) including multiparametric acquisition and reporting
    CategoryCategory III / advanced MRI quantitative procedures are listed and require prior authorization
    Authorization vendorEntries for 0648T/0649T reference Carelon for prior authorization routing
    78831 / 78832
    78831 / 78832 descriptorRadiopharmaceutical localization including tomographic (SPECT) studies with or without concurrently acquired CT for anatomical localization; minimum 2 areas or separate acquisitions
    SPECT variants78831 = SPECT minimum 2 areas or separate acquisitions; 78832 = SPECT with concurrently acquired CT, same minimum area requirements
    Authorization vendorCarelon is listed as the prior authorization reviewer for these codes
    Carelon
    Carelon — authorization managerCarelon is the named authorization/management entity for many molecular genetic test entries listed in the document
    Provider actionProviders must submit prior authorization requests to the manager identified (Carelon) for the specified molecular genetic CPT/PLA/U codes
    Effective datesMany code entries include effective or add dates that affect authorization routing; check individual code entries
    Molecular pathology procedure levels
    Molecular pathology levelsLevels 1–6 represent increasing complexity: Level 1 (81400) single variant; Level 2 (81401) 2–10 SNPs or methylation; Level 3 (81402) >10 SNPs or complex rearrangements; Level 4 (81403) single exon or >10 amplicons; Level 5 (81404) analysis of 2–5 exons; Level 6 (81405) analysis of 6–10 exons
    Coding rangeThese levels correspond to CPT 81400–81405 molecular pathology procedure level codes
    Use in PAPrior authorization listings reference these levels when indicating test complexity and requirements
    Genomic sequence analysis panel
    Genomic sequence analysis panel definitionA multi-gene testing panel that performs sequencing (and where specified, duplication/deletion analysis or RNA analysis) for a defined set of genes for a given hereditary or neoplastic indication; many codes require panels to include sequencing of a minimum number of named genes
    Panel requirementsIndividual CPT/U codes specify required gene lists, minimum gene counts, and whether duplication/deletion or RNA analysis is required
    Authorization implicationsProviders must document panel composition and indication when requesting prior authorization
    Whole mitochondrial genome
    Whole mitochondrial genome testSequence analysis of the entire mitochondrial genome with heteroplasmy detection for mitochondrial disorders (e.g., MELAS, MERRF, NARP, LHON)
    Relevant CPTCPT 81460 (whole mitochondrial genome) and related U/PLA codes reference heteroplasmy detection and whole-mitochondrial sequencing
    Authorization vendorCarelon is listed as prior authorization manager for mitochondrial genome testing entries
    Cell-free nucleic acid (plasma)
    cfDNA / ctDNA definitionPlasma-based interrogation of tumor-derived cell-free DNA/RNA for sequence variants, copy number variants and rearrangements
    Relevant CPTsCodes such as 81462–81464 reference cell-free nucleic acid (plasma) analyses for solid organ neoplasm panels
    Use caseUsed in oncology genomic panels and cfDNA-based assays requiring prior authorization
    Molecular Genetic Lab Testing (temporary/PLA codes)
    Temporary/PLA (U) codesProcedure descriptors in this section are temporary or PLA HCPCS-like codes (e.g., 0055U, 0078U) representing molecular/genetic tests such as targeted gene panels, cell-free assays, and expression profiling
    Coverage implicationThese temporary/PLA codes are listed as requiring prior authorization through the designated manager (Carelon) where indicated
    ExamplesThe document lists many U/PLA codes across oncology, transplant, and hereditary testing categories — review specific code entries for gene counts and methods
    Molecular genetic lab testing
    Molecular genetic lab testing (general)Molecular genetic laboratory testing entries include detailed test descriptors, gene panels, and methods and are listed as requiring prior authorization
    Provider requirementProviders must submit the specific test code and descriptor when requesting prior authorization
    Authorization managerCarelon is frequently listed as the prior authorization administrator for these tests
    Proprietary laboratory test billing codes (U-code)
    U-code definitionProprietary laboratory test billing codes (CPT Category II/III or proprietary laboratory codes) used to identify specific molecular genetic services (U/J/004xx series)
    ExamplesMultiple U/J codes (e.g., 0336U, 0340U, 0473U, 0543U) specify panel size, method (NGS, digital PCR), and indications in their descriptors
    Authorization implicationThese proprietary U/J codes require prior authorization and list Carelon as the authorization manager for many entries
    cell-free DNA (cfDNA) / circulating tumor DNA (ctDNA)
    cfDNA / ctDNA termcfDNA / circulating tumor DNA (ctDNA) assays are described for oncology and transplant monitoring (e.g., donor-derived cfDNA quantification), often requiring NGS or digital PCR methods
    Representative codesExamples include 0543U and 0544U for donor-derived cfDNA quantification and multiple 0485U–0487U/0473U entries for tumor cfDNA panels
    Authorization vendorCarelon is listed as the prior authorization manager for these cfDNA/ctDNA assays
    Next-generation sequencing (NGS)
    Next-generation sequencing (NGS)NGS refers to high-throughput sequencing methods used to detect SNVs, indels, CNVs, fusions, methylation patterns, and tumor mutation burden as described in multiple code entries
    Use in codesNumerous CPT and U-codes (e.g., 0473U, 0476U, 0530U, 0538U) specify NGS for large gene panels, cfDNA, and comprehensive tumor profiling
    Authorization implicationNGS-based tests typically require prior authorization and detailed panel composition documentation per code-specific requirements
    This part of the document enumerates modality-specific codes subject to prior authorization
    Scope — modality-specific PAThis document enumerates modality-specific codes (CT, MRI, MRA, CTA, MEG) that are subject to prior authorization; clinical indications are referenced but not detailed in these chunks
    Effective date for PA changesMany entries note effective 01/01/2025 for addition of site-of-care to medical necessity evaluation
    Primary PA vendorCarelon is listed repeatedly as the prior authorization reviewer/manager for many modality and molecular test codes

    Multiple new molecular genetic and proprietary U/J codes (including oncology, obstetrics, transplant, and broad genomic panels) were added with Carelon identified as the prior authorization administrator and effective add-dates of 07/01/2025 for many entries.

    2026-01-01vendor_assignment_updateLatest

    Selected molecular genetic U‑codes and certain medical transportation codes were reassigned to category 'Medical Transportation' with services management changed to Alacura/Carelon and additional effective add-dates (some added for 01/01/2026).